Literature DB >> 15909492

Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer.

Mi Yeon Choi1, Kwang Min Lee, June-Key Chung, Dong Soo Lee, Jae Min Jeong, Jae Gahb Park, Jung-Hoe Kim, Myung Chul Lee.   

Abstract

To determine the correlation between serum CEA level and the metabolic volume by FDG PET in postoperative patients with recurrent colorectal cancer, FDG PET was performed in 29 consecutive patients with recurrent or metastatic colorectal cancer whose CEA levels were higher than 5 ng/ml. A whole body emission scan was performed 60 minutes after injecting 370-555 MBq of F-18 FDG. "PET volume" and "PET metabolic volume" of tumors were measured on FDG PET images. Based on an isocontour plot of tumor mass at 2.5 SUV (standardized uptake value), the metabolically active tumor "PET volume" was calculated. "PET metabolic volume" was obtained by multiplying the "PET volume" by the mean SUV of the tumor. All recurrent or metastatic lesions were single or multiple lesions of measurable size (axial diameter > 1 cm, minimum "PET volume" 3.5 cm3), and were verified by operation or by other imaging modalities (CT or MRI). There was a linear associations between "PET volume" and serum CEA level. Further regression analysis by least squares showed a highly significant model with an equation of volume = 41.2 + 0.471 x CEA (r2 = 0.629). However, no such association was found between "PET metabolic volume" and serum CEA level according to the residual normality test. In conclusion, "PET volume" measured by FDG PET and serum CEA level in colorectal cancer are significantly correlated. Tumor volume determined by FDG PET can be used as an effective marker of tumor burden in postoperative patients with colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15909492     DOI: 10.1007/BF03027391

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  8 in total

1.  Use of computed tomography in the management of colorectal cancer.

Authors:  Cher Heng Tan; Revathy Iyer
Journal:  World J Radiol       Date:  2010-05-28

Review 2.  Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis.

Authors:  Yu-Yu Lu; Jin-Hua Chen; Chun-Ru Chien; William Tzu-Liang Chen; Shih-Chuan Tsai; Wan-Yu Lin; Chia-Hung Kao
Journal:  Int J Colorectal Dis       Date:  2013-02-14       Impact factor: 2.571

3.  Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer.

Authors:  Pengyue Shi; Xue Meng; Mengmeng Ni; Xindong Sun; Ligang Xing; Jinming Yu
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

4.  Unnecessary surgery can be avoided by judicious use of PET/CT scanning in colorectal cancer patients.

Authors:  Aliasger Amin; Anil Reddy; Robert Wilson; Madan Jha; Sumeet Miranda; Jasim Amin
Journal:  J Gastrointest Cancer       Date:  2012-12

Review 5.  Regional liver therapy using oncolytic virus to target hepatic colorectal metastases.

Authors:  Susanne G Carpenter; Joshua Carson; Yuman Fong
Journal:  Semin Oncol       Date:  2010-04       Impact factor: 4.929

Review 6.  KSNM60 in Clinical Nuclear Oncology.

Authors:  Seung Hwan Moon; Young Seok Cho; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-08-31

7.  A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer.

Authors:  Yuman Fong; Teresa Kim; Amit Bhargava; Larry Schwartz; Karen Brown; Lynn Brody; Anne Covey; Matthias Karrasch; George Getrajdman; Axel Mescheder; William Jarnagin; Nancy Kemeny
Journal:  Mol Ther       Date:  2008-11-18       Impact factor: 11.454

8.  Efficacy of 18F-FDG PET/CT in investigation of elevated CEA without known primary malignancy.

Authors:  Simon Sin-Man Wong; Wong L Yu; Ki Wang; Anil T Ahuja
Journal:  Indian J Radiol Imaging       Date:  2016 Jul-Sep
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.